On Friday, Cara Therapeutics Inc (NASDAQ: CARA) was 3.35% up from the session before settling in for the closing price of $0.41. A 52-week range for CARA has been $0.23 – $1.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 115.17%. With a float of $45.77 million, this company’s outstanding shares have now reached $54.85 million.
Let’s determine the extent of company efficiency that accounts for 55 employees. In terms of profitability, gross margin is 84.43%, operating margin of -944.9%, and the pretax margin is -1099.76%.
Cara Therapeutics Inc (CARA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cara Therapeutics Inc stocks. The insider ownership of Cara Therapeutics Inc is 16.56%, while institutional ownership is 24.70%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,064. In this transaction PRESIDENT AND CEO of this company sold 3,668 shares at a rate of $0.29, taking the stock ownership to the 168,768 shares. Before that another transaction happened on Aug 01 ’24, when Company’s PRESIDENT AND CEO sold 4,149 for $0.35, making the entire transaction worth $1,452. This insider now owns 172,436 shares in total.
Cara Therapeutics Inc (CARA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
You can see what Cara Therapeutics Inc (CARA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.38 in the next quarter
Technical Analysis of Cara Therapeutics Inc (CARA)
Looking closely at Cara Therapeutics Inc (NASDAQ: CARA), its last 5-days average volume was 11.46 million, which is a jump from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 59.45%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cara Therapeutics Inc’s (CARA) raw stochastic average was set at 67.02%, which indicates a significant increase from 67.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 193.53% in the past 14 days, which was higher than the 94.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2915, while its 200-day Moving Average is $0.4624. However, in the short run, Cara Therapeutics Inc’s stock first resistance to watch stands at $0.4751. Second resistance stands at $0.5277. The third major resistance level sits at $0.5952. If the price goes on to break the first support level at $0.3550, it is likely to go to the next support level at $0.2875. Should the price break the second support level, the third support level stands at $0.2349.
Cara Therapeutics Inc (NASDAQ: CARA) Key Stats
There are 54,856K outstanding shares of the company, which has a market capitalization of 23.96 million. As of now, sales total 20,970 K while income totals -118,510 K. Its latest quarter income was 2,560 K while its last quarter net income were -12,480 K.
